Esophageal cancer has one of the poorest survival rates of any malignancy. Even among patients diagnosed before the disease has spread, fewer than half survive for five years. A new study led by doctors at Dallas’ Baylor University Medical Center found that an immunotherapy drug doubled disease-free survival times for those with operable tumors and lowered the risk of cancer …
Read More »A ‘major step forward’ for patients with esophageal cancer
April 1, 2021